Clinical Trials Logo

Filter by:
NCT ID: NCT06361108 Not yet recruiting - Clinical trials for Diabetic Peripheral Neuropathic Pain

Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of YJ001 for Spray Use in Patients With Diabetic Peripheral Neuropathic Pain

Start date: April 10, 2024
Phase: Phase 1
Study type: Interventional

This Phase I, randomized, double-blind and placebo controlled study is to evaluate the safety, tolerability, and PK, and to preliminarily assess the efficacy of topically administered YJ001 in a multiple-ascending dose (MAD) fashion in the patients with DPNP. The study will be conducted at a single study center. In this study, 2 cohorts (N=24, 12 subjects for each cohort), each cohort will consist of 10 active and 2 placebo, with approximately equal numbers of male and female subjects. Each subject will be administered a single dose of YJ001 as multiple sprays topically on both feet and below the ankle in the morning on Day 1 and Day 2, and will be administered as twice daily doses once in the morning and the other in the evening (with an interval of 11 to 13 h) from Day 3 through Day 11.

NCT ID: NCT06361095 Not yet recruiting - Depression Clinical Trials

Confirmatory Efficacy Trial of Attention Bias Modification for Depression

Start date: May 1, 2024
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to compare the efficacy of two related, but different ABM (Attention Biased Modification) treatments for depression in adults with elevated symptoms of depression. The main aims are: - Aim 1:examine whether gamified ABM leads to greater change in the primary and secondary outcomes than sham ABM - Aim 1: establish that gamified ABM is at least as effective as traditional ABM. - Aim 2: identify moderators of ABM efficacy and mechanisms responsible for its efficacy. - Aim 3: Identify the durability of ABM on depression symptoms during short-term follow-up Participants will complete self-report questionnaires, complete eye-tracking tasks, and be clinically assessed through interviews by clinician researchers. If there is a comparison group: Researchers will compare sham, traditional, and gamified treatment groups to see if they moderate symptoms of depression.

NCT ID: NCT06361056 Recruiting - Breast Cancer Clinical Trials

Mobile Health App to Promote Participation of Black Women in Breast Cancer Clinical Trials

Start date: May 2, 2022
Phase: N/A
Study type: Interventional

This study explores the overall feasibility, impact, and satisfaction of using the "mHealth app" on clinic workflow for Black or African American women diagnosed with breast cancer. The "mHealth app" which can be used as a platform to share clinical trial education and communication, was created and tested in previous steps of this study.

NCT ID: NCT06360952 Not yet recruiting - Neutropenia Clinical Trials

A Comparator Study of a Tasso Device Blood Sample to Traditional Venous Blood Sample for CBC

Start date: May 31, 2024
Phase:
Study type: Observational

This study will evaluate the feasibility of using capillary blood samples collected with the Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or other blood cell disorders. This investigation will include a minimum of 40 sample sets from unique patients.

NCT ID: NCT06360822 Recruiting - Lung Cancer Clinical Trials

Increasing Equity in Lung Cancer Screening

LUCARE
Start date: December 1, 2023
Phase: N/A
Study type: Interventional

The overall objective of this mixed methods study is to: 1) Refine the Emergency Department Lung Cancer Screening (ED-LCS) intervention using qualitative interviews among key stakeholders; 2) pilot test the ED-LCS intervention evaluating the intervention efficacy, acceptability, and feasibility; and 3) provide an in-depth description of stakeholders' experiences with the ED-LCS intervention for future refinement.

NCT ID: NCT06360783 Active, not recruiting - COVID-19 Clinical Trials

COVID-19 Quick Start - Test and Treat in Africa

Start date: February 1, 2023
Phase:
Study type: Observational

Duke University and the Clinton Health Access Initiative (CHAI), in partnership with the Ministries of Health (MoH) of Ghana, Malawi, Rwanda, Zambia, and Zimbabwe, aim to assess the implementation and impact of COVID-19 test -and -treat (T&T) demonstration programs

NCT ID: NCT06360718 Recruiting - Leukemia Clinical Trials

Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.

Start date: February 3, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to measure the effects of using a storybook versus standard child life intervention with parents of children newly diagnosed with leukemia on parental stress. The main questions it aims to answer are: - What effect will the storybook have on parent/legal guardian stress at three timepoints: baseline, discharge, and follow up? - Will this storybook impact parent/legal guardian comfort levels and improve their child's understanding? Participants will be asked to complete surveys at three timepoints, prior to and following child life intervention and about 3.5 months later. During child life interventions, participants will receive resources and support to explain leukemia to their school aged, 3-16-year-old, child (patient or sibling). Researchers will compare Intervention and Control Groups to see if parental stress is lower in those who received the storybook in addition to the standard child life intervention versus the standard child life intervention alone.

NCT ID: NCT06360705 Recruiting - Clinical trials for Vulvar Lichen Sclerosus

StrataMGT for the Treatment of Vulvar Lichen Sclerosus

Start date: April 2024
Phase: N/A
Study type: Interventional

This study is designed to evaluate the efficacy and safety of StrataMGT for the treatment of vulvar lichen sclerosus.

NCT ID: NCT06360588 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

Start date: June 19, 2018
Phase: Phase 2
Study type: Interventional

The phase II MATCH treatment trial tests how well copanlisib works to treat patients with cancer with PTEN loss. Copanlisib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth.

NCT ID: NCT06360575 Active, not recruiting - Clinical trials for Refractory Multiple Myeloma

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Start date: May 30, 2016
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial tests how well crizotinib works to treat patients with cancers with MET exon 14 deletion genetic changes. Crizotinib is in a group of medications called tyrosine kinase inhibitors. It works by blocking enzymes that cancer cells need to grow and spread. It may also prevent the growth of new blood vessels that tumors need to grow.